FDA Drug recall D-0493-2025
UMOVY ACIDO HIALURONICO, Conenido: 30 capletas de 850mg, distribuido por: EREN NATURAL S.A. DE C.V, Zappan, Jal
- FDA Drug
- Class I
- completed
- Published 2025-06-25
On 2025-06-25 the FDA classified a Class I recall of UMOVY ACIDO HIALURONICO, Conenido: 30 capletas de 850mg, distribuido por: EREN NATURAL S.A. DE C.V, Zappan, Jal by Umary Usa Com, citing marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone and Diclofenac.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0493-2025 |
| Classification | Class I |
| Status | completed |
| Initiated | 2025-05-21 |
| Published | 2025-06-25 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Umary Usa Com |
| Distribution | US |
Product
UMOVY ACIDO HIALURONICO, Conenido: 30 capletas de 850mg, distribuido por: EREN NATURAL S.A. DE C.V, Zappan, Jal. C.P, UPC 7503046054134
Reason
Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone and Diclofenac.
Identifiers
| upc | 7503046054134 |
|---|---|
| code_info | All Lots; All Expiration Dates. |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: completed.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0493-2025%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.